RESUMO
We performed Illumina whole-genome sequencing on a carbapenem-resistant Pseudomonas aeruginosa strain isolated from a cystic fibrosis patient with chronic airway colonization. The draft genome comprises 6,770,411 bp, including the carbapenemase bla NDM-1 and the extended-spectrum beta-lactamase bla PME-1 This isolate harbors 3 prophages, 14 antibiotic resistance genes, and 257 virulence genes.
RESUMO
Previous research has shown that structural features such as voice changes, jingle onsets, and production effects in a radio broadcast elicit cardiac orienting responses. In fact, the voice change has been shown to reliably elicit orienting without habituation after several repetitions. However, repeated onsets of two other auditory structural features-jingles and production effects-did result in habituation when the participant was exposed to them embedded in an audio production absent a central cognitive task. This article presents two experiments testing the possibility that adding a central task prevents the development of a robust neural model of the auditory structural features necessary for habituation. In both studies, results show that adding a primary cognitive task eliminated habituation to jingles and production effects. However, varying the cognitive load of the primary task across two levels of difficulty had no significant effect on habituation.
RESUMO
Carbapenems, our one-time silver bullet for multidrug resistant bacterial infections, are now threatened by widespread dissemination of carbapenem-resistant Enterobacteriaceae (CRE). Successful expansion of Enterobacteriaceae clonal groups and frequent horizontal gene transfer of carbapenemase expressing plasmids are causing increasing carbapenem resistance. Recent advances in genetic and phenotypic detection facilitate global surveillance of CRE diversity and prevalence. In particular, whole genome sequencing enabled efficient tracking, annotation, and study of genetic elements colocalized with carbapenemase genes on chromosomes and on plasmids. Improved characterization helps detail the co-occurrence of other antibiotic resistance genes in CRE isolates and helps identify pan-drug resistance mechanisms. The novel ß-lactamase inhibitor, avibactam, combined with ceftazidime or aztreonam, is a promising CRE treatment compared to current colistin or tigecycline regimens. To halt increasing CRE-associated morbidity and mortality, we must continue quality, cooperative monitoring and urgently investigate novel treatments.